Conditions: Healthy
Keywords: Single ascending doses pharmacokinetics safety tolerability healthy volunteers cognitive impairment associated with schizophrenia (CIAS)
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 12
Healthy volunteers: yes

Brief summary:
This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of single ascending doses in healthy volunteers

Detailed description:
This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.

Arms:
arm 1: Participants received 1 single dose of placebo, PF-04958242 0.6 mg, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing. arm 2: Participants received 1 single dose of PF-04958242 0.35 mg, placebo, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing. arm 3: Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.

Interventions: intervention 1: PF-04958242 intervention 2: Placebo
Intervention descriptions: intervention 1: Administered as specified in treatment arm intervention 2: Administered as specified in treatment arm

Protocol document: